Kymera Therapeutics to Participate in Upcoming September Conferences

Rhea-AI Summary

Kymera Therapeutics (NASDAQ: KYMR) announced that its Co-Founder, President, and CEO, Nello Mainolfi, will participate in several upcoming investor conferences. Key events include the 2022 Wells Fargo Healthcare Conference on September 7 at 1:20 p.m. ET, the Morgan Stanley 20th Annual Global Healthcare Conference on September 14 at 8:00 a.m. ET, and the 2022 Guggenheim Nantucket Therapeutics Conference on September 28 at 2:15 p.m. ET. Presentation webcasts will be accessible on Kymera's website, with archived replays available for 90 days.

WATERTOWN, Mass., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, announced that Nello Mainolfi, PhD, Co-Founder, President and CEO, will participate in Fireside Chats at the following upcoming investor conferences:

• 2022 Wells Fargo Healthcare Conference: September 7th at 1:20 p.m. ET
• Morgan Stanley 20th Annual Global Healthcare Conference: September 14th at 8:00 a.m. ET
• 2022 Guggenheim Nantucket Therapeutics Conference: September 28th at 2:15 p.m. ET
  

Presentation webcasts will be available under "Events and Presentations" in the Investors section of the Company's website at www.kymeratx.com. Archived webcast replays will be available on the website for approximately 90 days.

About Kymera Therapeutics
Kymera is a biopharmaceutical company pioneering the field of targeted protein degradation, a transformative approach to address disease targets and pathways inaccessible with conventional therapeutics. Kymera’s Pegasus platform is a powerful drug discovery engine, advancing novel small molecule therapies candidates designed to harness the body’s innate protein recycling machinery to degrade dysregulated, disease-causing proteins. With a focus on undrugged nodes in validated pathways, Kymera is advancing a pipeline of novel therapeutic candidates designed to address the most intractable of pathways and provide new treatments for patients. Kymera’s initial programs target IRAK4, IRAKIMiD, and STAT3 within the IL-1R/TLR or JAK/STAT pathways, providing the opportunity to treat patients with a broad range of immune-inflammatory diseases, hematologic malignancies, and solid tumors. For more information, visit www.kymeratx.com.

Investor Contact:
Bruce Jacobs
Chief Financial Officer
investors@kymeratx.com
857-285-5300

Chris Brinzey
Managing Director, Westwicke
chris.brinzey@westwicke.com
339-970-2843

Media Contact:
Todd Cooper
Senior Vice President, Corporate Affairs
media@kymeratx.com
857-285-5300

FAQ

What dates will Kymera Therapeutics participate in investor conferences in September 2022?

Kymera Therapeutics will participate in investor conferences on September 7, September 14, and September 28, 2022.

Where can I find the webcasts for Kymera Therapeutics' investor presentations?

Webcasts for Kymera Therapeutics' investor presentations will be available in the 'Events and Presentations' section of their website.

What is the focus of Kymera Therapeutics' drug development?

Kymera Therapeutics focuses on targeted protein degradation to develop novel small molecule therapies for various diseases.

What are the time slots for Kymera Therapeutics' upcoming presentations?

Kymera will present on September 7 at 1:20 p.m. ET, September 14 at 8:00 a.m. ET, and September 28 at 2:15 p.m. ET.